Multiple treatments for metastatic prostate cancer have similar efficacy, leaving patients with complicated treatment choices. Shared decision-making can facilitate difficult treatment decisions, but the extent to which this is used for metastatic prostate cancer is unknown.
After radiation therapy (RT), circulating plasma cell-free DNA (cfDNA) released in response to RT damage to tissue can be measured within hours. We examined for a correlation between cfDNA measured during the first week of therapy and early and late gastrointestinal (GI) and genitourinary (GU) toxicity.
To determine factors that influence insurance approval for definitive proton therapy (PT) for prostate cancer. Between 2014 and 2018, 1592 insured patients with localized prostate cancer were evaluated and recommended to undergo definitive PT; 547 patients (34.
Active surveillance (AS) is a safe treatment option for men with low-risk, localized prostate cancer. However, the safety of AS for patients with intermediate-risk prostate cancer remains unclear. We identified men with NCCN-classified low-risk and favorable and unfavorable intermediate-risk prostate cancer diagnosed between 2001 and 2015 and initially managed with AS in the Veterans Health […]
To assess the feasibility, safety, and efficiency of bilateral inguinal lymphadenectomy using simultaneous double laparoscopies for penile cancer. We reviewed retrospectively the records of 65 patients who underwent inguinal lymph nodes dissection (ILND) for penile cancer from January 2012 to May 2019.
Upper tract urinary cancer recurrence (UTUCR) after radical cystectomy (RC) is outcome-limiting. Surgical recommendations on intraoperative performance of frozen section analysis (FSA) and management of positive ureteral margin (PUM) are lacking.
Due to a rising annual incidence of bladder cancer, there is a growing need for development of new strategies for treatment. In 2018, the World Cancer Research Fund and other groups reported that there were ~550,000 new cases worldwide of bladder cancer.
Intravesical instillations of BCG are recommended for the treatment of high-risk non-muscle-invasive bladder cancer. However, their prolonged use remains limited by the associated potentially serious adverse effects or complications.
Nivolumab plus ipilimumab (NIVO-IPI) is one of the treatment standards for previously untreated clear cell renal cell carcinoma (RCC). Furthermore, the 20% progressive disease (PD) criterion as the best objective response was reportedly higher in the NIVO-IPI clinical trial than that in the other immune checkpoint inhibitor (ICI) combined regimens.1-4 There is an urgent need for […]
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a geomedical oncologist at Dana-Farmer Cancer Institute. I am so excited to have here with me today, Dr. Ben Miron, who’s a senior fellow at the Fox Chase Cancer Center in Philadelphia. Thank you so much for being here with me today. Ben Miron: Thank […]
